Plaque-Type Psoriasis Clinical Trial
Official title:
A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
This study is being conducted to obtain efficacy and tolerability data for two clobetasol propionate therapies in the treatment of plaque-type psoriasis. Subjects will be randomized to only one of the two therapies for treatment throughout the study. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01936688 -
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
|
Phase 3 | |
Completed |
NCT00763503 -
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
|
Phase 2 | |
Completed |
NCT00773734 -
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
|
Phase 2 | |
Completed |
NCT01636687 -
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
|
Phase 3 | |
Completed |
NCT01258088 -
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
|
Phase 1 | |
Completed |
NCT01132612 -
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT00625326 -
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
|
Phase 2 | |
Completed |
NCT01412944 -
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
|
Phase 3 | |
Completed |
NCT00521339 -
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT01876875 -
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis
|
Phase 4 |